PHVS Pharvaris N.V.
Price Chart
Executive Summary
Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) used in clinical trials for on-demand treatment of hereditary angioedema (HAE), supporting the endpoint hierarchy in its ongoing Phase 3 RAPIDe-3 trial of deucrictibant. The findings reinforce the patient-centric design of the trial and may influence future HAE treatment assessments.
Actionable Insight
Traders should monitor upcoming catalysts: NDA submission for deucrictibant IR capsule (H1 2026) and topline data from CHAPTER-3 (Q3 2026), which are more likely to move the stock than this validation study.
Key Facts
- Study validates PGI and AMRA instruments as reliable tools for assessing patient experience during HAE attacks.
- Findings support the hierarchical endpoint structure in the Phase 3 RAPIDe-3 trial of oral deucrictibant for on-demand HAE treatment.
- End of Progression™ was identified as the first meaningful milestone, followed by symptom relief and resolution.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland for bradykinin-mediated angioedema.
- NDA submission for deucrictibant immediate-release capsule expected in first half of 2026; CHAPTER-3 topline data expected Q3 2026.
Financial Impact
No direct financial impact disclosed; supports clinical development pathway without immediate revenue or cost implications.
Risk Factors
- Regulatory uncertainty regarding approval of deucrictibant despite validated endpoints.
- Clinical trial results may not replicate prior efficacy in larger studies.
- Competition from existing and emerging HAE therapies could limit market adoption.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253609 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
16d ago
|
Press Release
| $30.16 $31.09 | ▲ +3.08% | ▲ +5.61% | $30.72 (+1.86%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▲ +2.27% | ▲ +1.80% | $30.72 (+4.24%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▼ −2.27% | ▼ −1.80% | $30.72 (−4.24%) |
|
May 22, 2026
23d ago
|
Insider Cluster
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.63% | $30.72 (+3.50%) |
|
May 21, 2026
24d ago
|
144
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.61% | $30.72 (+3.50%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 20, 2026
25d ago
|
144
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 19, 2026
26d ago
|
Insider Cluster
| $29.45 $29.86 | ▲ +1.39% | ▼ −0.41% | $30.72 (+4.31%) |
|
May 12, 2026
4w ago
|
Press Release
| $32.94 $28.95 | ▼ −12.11% | ▼ −10.95% | $30.72 (−6.74%) |
|
May 11, 2026
4w ago
|
6-K
| $31.25 $28.81 | ▼ −7.81% | ▼ −7.89% | $30.72 (−1.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access